Digital pathology adoption and AI image analysis show significant potential, but return on investment (ROI) remains a challenge. The lack of reimbursement for FDA-cleared digital pathology (DP) solutions is a major barrier to widespread adoption. The DPA Reimbursement Task Force has a mission to 'To define and shape the pathway to reimbursement for digital pathology solutions enabling broad market access and delivery of value to patients and stakeholders. This session will provide an update on the key work of the DPA Reimbursement Task Force and provide a detailed look into the framework for DP AI reimbursement that the task force is pursuing. In addition, we will hear from experts on key changes to the reimbursement landscape in the US and important trends that are shaping how these solutions are being brought to the market.

Learning Objectives: 

1. Update DPA members on the progress and priorities of the Reimbursement Task Force
2. Provide an overview of the current Digital Pathology reimbursement landscape and identify key trends that will impact both WSI and DP AI algorithms
3. Discuss the implications of US reimbursement trends for the Digital Pathology industry with a panel of experts from the DPA Reimbursement Task Force, along with select outside consultants